Regulatory & market landscape
Amycretin arrived amid intense interest in the obesity market, and its novel design drew attention fast.
A drug the market is watching, not yet selling
Amycretin arrived amid intense interest in the obesity market, and its novel design drew attention fast. Yet it is approved nowhere in the public record, its phase 3 program is enrolling rather than reporting, and a "research peptide" shadow market has already formed around an unavailable, unverified drug.
This unit maps the regulatory reality, the transition from dose-finding to confirmatory trials, the athlete question, and the honest bottom-line verdict on a promising but still-unproven molecule. It also flags one naming trap: the molecule was renamed zenagamtide in 2026, and a search under only one name misses half the record.
Key terms
The regulatory status
The headline is simple: amycretin is approved nowhere in the public record. The openFDA label search returns no matches for the name, the labeling database returns zero documents, and the sponsor's own most recent release lists zenagamtide among medicines that are not approved in the United States. Novo Nordisk announced in June 2025 that both formulations would advance into phase 3 development in weight management, and the AMAZE program opened its first trial in February 2026. That is the start of the approval journey, not the end: a trial that is enrolling has proved nothing.
The anti-doping row below is read straight off WADA's own documents rather than off commentary. The 2026 Monitoring Program lists markers of semaglutide and tirzepatide, in- and out-of-competition, and the 2026 Prohibited List, which came into effect on 1 January 2026, contains neither amycretin nor zenagamtide anywhere in its text. Amycretin is named on neither document.
The regulatory picture is coherent: a novel drug with striking early data but no confirmatory evidence yet, now running the large trials approval requires. The dependence on a full phase 3 program is important; early-phase readouts, however eye-catching, do not make a filing.
AdvancedWhy phase 3 will take years
The registered phase 3 trials here are large and long: 1150 participants estimated for AMAZE 1 and 5610 for the heart-failure outcome trial, before follow-up, analysis and regulatory review. Amycretin also has two formulations, each needing its own program, and its flagship obesity trial (AMAZE 1) reads out its primary endpoint at week 84 with a primary completion date in 2029. Even on an aggressive timeline, that puts any possible approval years away, and every step could reshape the picture, including the possibility that the striking small-arm numbers do not hold up at scale.